Showing 1351-1360 of 1655 results for "".
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r
- How Best to Combat Post-Keratoplasty Infections Isn’t Always Clearhttps://modernod.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/Infection is one of the most dreaded complications after ocular surgery. Although it is considered rare, the rate of fungal infections after corneal transplantation is nonetheless increasing in the United States. As detailed in a recent r
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatmenthttps://modernod.com/news/acucela-announces-publication-assessing-the-role-of-emixustat-hydrochloride-in-retinal-degeneration-treatment/2477209/Acucela announced the publication of an article concerning the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Drug Discovery Today. The published article, “Pharmacotherapy for Metabolic and Cellular Stress in Degenerative R
- RightEye: New Research Demonstrates Reliability of Eye Tracking Data to Identify and Measure Severity of Traumatic Brain Injurieshttps://modernod.com/news/righteye-new-research-demonstrates-reliability-of-eye-tracking-data-to-identify-and-measure-severity-of-traumatic-brain-injuries/2476832/RightEye announced the results of a recent study published in the peer-reviewed journal Concussion that shows how RightEye’s FDA-cleared technology accurately measures deficits in certain eye movements that r
- BlephEx Asserts Claims of Patent Infringement and False Advertising Against Myco Industrieshttps://modernod.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced that it has asserted claims of willful patent infringement and false advertising against Myco Industries and John R
- New President/CEO at The Glaucoma Foundationhttps://modernod.com/news/new-president-ceo-at-the-glaucoma-foundation/2476529/The Board of Directors of The Glaucoma Foundation (TGF) has announced the appointment of Elena Sturman as President and Chief Executive Officer, following the retirement of Scott R. Christensen, who held the position since 2002. She wi
- Cataract-Surgery Adjuncts Improve Vision in Diabetic Macular Edemahttps://modernod.com/news/cataract-surgery-adjuncts-improve-vision-in-diabetic-macular-edema/2476367/Both intravitreous bevacizumab (BVB) and triamcinolone acetate (TA) improve outcomes when given as an adjunct to cataract surgery in patients with diabetic macular edema (DME), a new randomized controlled trial shows., according to a Reuters r
- Sue Anschutz-Rodgers Eye Center: A Highly Visible Legacy of Longstanding Philanthropic Partnershiphttps://modernod.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/The University of Colorado Anschutz Medical Campus and UCHealth announced the naming of the UCHealth Eye Center program for philanthropist Sue Anschutz-Rodgers, who has made leadership gifts to accelerate innovative r
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda